Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759555 | 0.75 | KDR (0.37) | KDM4EALDH1A1HTTHSD17B10MEN1 | |
| SCHEMBL11002575 | 0.69 | — | — | |
| SCHEMBL5557928 | 0.68 | MAPT (0.31) | MAPTAGTR1 | |
| SCHEMBL4760137 | 0.67 | KDM4E (0.33) | KDM4EALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL4760142 | 0.67 | KDM4E (0.41) | KDM4EALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL4760122 | 0.64 | TSHR (0.47) | KDM4EALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL21960369 | 0.63 | ALDH1A1 (0.35) | KDM4EALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL7336875 | 0.62 | CYP11B1 (0.42) | KDM4EALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL23046922 | 0.61 | TSHR (0.51) | KDM4EALDH1A1LMNAHTTGRM2 | |
| SCHEMBL4759867 | 0.60 | NPC1 (0.47) | ALDH1A1SMN1; SMN2MEN1RECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470698-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2007-10-25 | — | — | US | disclosed |
| US-7271171-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060040959-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-02-23 | — | — | US | disclosed |
| US-6921825-B2 | Adenosine A3 receptor modulators | KING PHARMACEUTICUALS RESEARCH & DEVELOPMENT, INC. (US) | 2005-07-26 | — | — | US | disclosed |
| US-20030144266-A1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6448253-B1 | Adenosine A3 receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6407236-B1 | TUMOR DIAGNOSIS; ANTIINFLAMMATORY AGENTS; ANTIISCHEMIC AGENTS; ANTIDEPRESSANTS | MEDCO RESEARCH, INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2000015231-A9 | ADENOSINE A3 RECEPTOR MODULATORS | MEDCO RES INC (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000015231-A1 | ADENOSINE A3 RECEPTOR MODULATORS | MEDCO RESEARCH INC. (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-1995001356-A1 | 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES HAVING ANTAGONISTIC ACTIVITY ON ADENOSINE A2 RECEPTOR | SCHERING-PLOUGH S.P.A. (IT) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040959-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | KDM4E 4280/4885ALDH1A1 549/4885LMNA 1938/4885 |
| US-20070249641-A1 | ADENOSINE A3 RECEPTOR MODULATORS | ADORA3, ADORA2A, ADORA1 | KDM4E 4280/4885ALDH1A1 549/4885LMNA 1938/4885 |
| US-20030144266-A1 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | KDM4E 4491/4885ALDH1A1 620/4885LMNA 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.